| Ticker: BIOP | 3 Morgan | |
| Exchange: NASDAQ-National Market | Irvine, California 92718 | |
| Industry: Manufacturing | (714) 460-7800 |
| Type of Shares: | Common Shares | Filing Date: | 3/19/96 | |
| U.S. Shares: | 2,250,000 | Offer Date: | 5/1/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $13.00 - $15.00 | |
| Primary Shares: | 2,250,000 | Offer Price: | $15.00 | |
| Secondary Shares: | 0 | Gross Spread: | $1.05 | |
| Offering Amount: | $31,500,000 | Selling: | $0.60 | |
| Expenses: | $800,000 | Reallowance: | $0.10 | |
| Shares Out After: | 9,334,380 |
| Manager | Tier | Phone |
| Robertson, Stephens & Company | Lead Manager | (415) 989-8500 |
| Piper Jaffray Incorporated | Co-manager | (612) 342-6000 |
| Auditor: Deloitte & Touche | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 6/30/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $0.08 | $1.81 | $0.00 | Assets: | $5.45 |
| Net Income: | -$2.47 | -$2.55 | -$1.62 | Liabilities: | $10.37 |
| EPS: | -$0.55 | -$0.33 | Equity: | -$4.92 | |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company designs, develops , manufactures and markets products for the diagnosis of breast cancer. In April 1995, the company received clearance from the FDA to market its Mammotome Biopsy System. The Company has designed the Mammotome Biopsy System to combine the advantages of open surgical biopsy and less-invasive procedures such as core needle biopsy. The Mammotome Biopsy System is comprised of a disposable Mammotome probe and a motorized drive unit that is mounted on a stereotactic x-ray imaging table. In contrast to open surgical biopsy, the Mammotome procedure is performed under local anesthesia in an outpatient setting, is less costly and results in less disfigurement for the patient. The procedure requires a single insertion of the probe and can be performed in 20 minutes. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used to expand sales and marketing activities, increase manufacturing capabilities, and fund research and development, with the remainder to be used for working capital and general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.